Cargando…
Correction: Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer
Autores principales: | Liu, Dongyan, Hou, Xiaonan, Wu, Wangyu, Zafagnin, Valentina, Li, Yunjian, Correia, Cristina, Zhao, Zhiyang, Zhao, Chenggang, Liu, Zhirong, Zhang, Tao, Fang, Zhiyou, Wang, Hongzhi, Xu, Chao, Weroha, Saravut J., Kaufmann, Scott H., Dai, Haiming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548556/ https://www.ncbi.nlm.nih.gov/pubmed/34702806 http://dx.doi.org/10.1038/s41419-021-04219-0 |
Ejemplares similares
-
Constitutive BAK/MCL1 complexes predict paclitaxel and S63845 sensitivity of ovarian cancer
por: Liu, Dongyan, et al.
Publicado: (2021) -
Chemotherapy-induced pyroptosis is mediated by BAK/BAX-caspase-3-GSDME pathway and inhibited by 2-bromopalmitate
por: Hu, Lei, et al.
Publicado: (2020) -
MCL-1 Inhibitor S63845 Distinctively Affects Intramedullary and Extramedullary Hematopoiesis
por: Zhang, Hexiao, et al.
Publicado: (2023) -
Constitutive BAK activation as a determinant of drug sensitivity in malignant lymphohematopoietic cells
por: Dai, Haiming, et al.
Publicado: (2015) -
MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells
por: Mukherjee, Nabanita, et al.
Publicado: (2020)